Angiogenesis is essential for tumor growth and development of metastases in human breast cancer. Randomized studies have shown thatï¿½bevacizumabï¿½(inhibitor of VEGF) combined with taxane-based regimens increases response rates and prolongs Progression-Free Survival (PFS) of patients with Metastaticï¿½Breast Cancerï¿½(MBC). However predictive orï¿½prognostic markers that identify the appropriate target population, thus improving the cost-effectiveness ratio of this treatment, are still needed. In this retrospective analysis, we investigated the impact of traditional clinical and pathological features in order to identify the subgroups of patients who derive the greatest benefit from antiangiogenic-agents.
Pistelli M, Ballatore Z, De Lisa M, Caramanti M, Pagliacci A (2014) Paclitaxel and Bevacizumab in First Line-Treatment Patients with HER-2 Negative Advanced Breast Cancer: Who could Benefit?. Chemotherapy 3:127